Cost-effectiveness of a cardiovascular polypill strategy (aspirin, atorvastatin, ramipril) for the secondary prevention of cardiovascular disease based on real life improvement in risk factor control
Event: ESC Preventive Cardiology 2021
Topic: Health Economics
Session: Rapid fire abstracts - Secondary Prevention and Rehabilitation
ESC 365 is supported by
